CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge

• The surge in revenue was driven by DefenCath sales, which generated $97.5 million during the quarter.
• First-quarter earnings came in at $0.43 per share, beating estimates of $0.37 per share.
• Cormedix raised its full-year 2026 net revenue guidance to between $325 million and $345 million, up from its earlier forecast of $300 million to $320 million.

Shares of CorMedix (CRMD) skyrocketed more than 18% on Thursday after the medical device maker delivered blockbuster first-quarter results, with revenue surging 226%, crushing Wall Street expectations, and prompting the company to raise its full-year 2026 earnings outlook.

CRMD shares are trading at their highest levels since Jan. 8, 2026.

Strong DefenCath Sales Boost CRMD’s Q1 Revenue

CorMedix reported strong Q1 results, with revenue coming at $127.4 million, far exceeding Wall Street’s guidance of around $105 million, according to Fiscal.ai data. Meanwhile, earnings came in at $0.43 per share, beating estimates of $0.37.

The surge in revenue was driven by DefenCath sales, which generated $97.5 million during the quarter. DefenCath is a U.S. Food and Drug Administration-approved solution used to help prevent infections and blood clotting in central venous catheters used by dialysis patients.

“DefenCath continues to exceed expectations despite pending TDAPA expiration and demonstrates strong underlying utilization demand,” said Joseph Todisco, CorMedix Chairman & CEO.

CRMD Raises FY2026 Outlook

Following the standout performance, Cormedix raised its full-year (FY) 2026 net revenue guidance to between $325 million and $345 million, up from its earlier forecast of $300 million to $320 million.

CorMedix also lifted its adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook to a range of $115 million to $135 million, compared with previous guidance of $100 million to $125 million.

What Is Retail’s Take On CRMD?

Retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.

One user expects the stock to climb to $15. It's currently trading at around $8.6.

Another user highlighted the status of the firm’s share buyback program.

In February, CorMedix announced a $75 million share repurchase program, which is expected to continue till Dec. 31, 2027. The company said it expects to begin repurchasing shares in Q1 2026.

The stock has been under selling pressure so far this year, with a 40% decline.

Read also: Biogen’s Latest Alzheimer’s Bet Didn’t Fully Succeed – But Still Sent BIIB Stock Soaring

For updates and corrections, email newsroom[at]stocktwits[dot]com.